welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
A Randomised, Double Blind, Placebo Controlled Study of Celecoxib, a Selective Cyclooxygenase 2 Inhibitor, on Duodenal Polyposis in Familial Adenomatous Polyposis
source: Gut Journal
year: 2002
authors: Phillips R K, Wallace M H, Lynch P M, Hawk E, Saunders B P, Wakabayashi N, Gordon G B, Shen Y
summary/abstract:BACKGROUND : Non-selective cyclooxygenase (COX) inhibitors (non-steroidal anti-inflammatory drugs) inhibit large bowel carcinogenesis in patients with familial adenomatous polyposis (FAP). Their role in the duodenum of these patients is less certain. The disease modifying activity of specific COX-2 inhibitors has not been explored in humans.
PATIENTS AND METHODS : This was a randomised, double blind, placebo controlled study of celecoxib (100 mg twice daily (n=34) or 400 mg twice daily (n=32)) versus placebo (n=17), given orally twice daily for six months to patients with FAP. Efficacy was assessed qualitatively by blinded review of shuffled endoscopy videotapes comparing the extent of duodenal polyposis at entry and at six months and quantitatively by measurement of the percentage change in duodenal area covered by discrete and plaque-like adenomas from photographs of high and low density polyposis.
RESULTS : Shuffled and blinded video review showed a statistically significant effect of 400 mg twice daily celecoxib compared with placebo treatment (p=0.033) with all five independent observers scoring a beneficial effect. Overall, patients taking celecoxib 400 mg twice daily showed a 14.5% reduction in involved areas compared with a 1.4% for placebo (p=0.436). However, patients with clinically significant disease at baseline (greater than 5% covered by polyps) showed a 31% reduction in involved areas with celecoxib 400 mg twice daily compared with 8% on placebo (p=0.049).
CONCLUSIONS : A panel of five endoscopists found a significant reduction in duodenal polyposis after six months of treatment with celecoxib 400 mg twice daily. COX-2 inhibition may help this otherwise untreatable condition.
organization: Imperial Cancer Research Fundread more full text source
expertly curated content related to this topic
-
Impact of a Hospital-based Register on the Management of Familial Adenomatous PolyposisColorectal cancer in familial adenomatou...
-
Thirty Years of the Ileal-Anal Pouch and BeyondStill referred to as a new surgical proc...
-
Ileal Pouch Anal Anastomosis: An Overview of Surgery, Recovery, and Achieving Postsurgical ContinenceIleal pouch anal anastomosis (IPAA) is a...
-
Body Image, Cosmesis, Quality of Life, and Functional Outcome of Hand-Assisted Laparoscopic Versus Open Restorative ...BACKGROUND : This study aimed to compare...
-
Inactivation of the APC Gene is Constant in Adrenocortical Tumors from Patients with Familial Adenomatous Polyposis ...PURPOSE : In adrenocortical tumors (ACT)...
-
Nonsteroidal Anti-Inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical IssuesNumerous experimental, epidemiologic, an...
-
Cancer Prevention Pharmaceuticals, Inc. and Tillotts Pharma AG Sign Licensing Agreement for CPP-1X/sulindac in Europ...Cancer Prevention Pharmaceuticals, Inc. ...